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One critical event in reprogramming to pluripotency
is erasure of the somatic transcriptional program of
starting cells. Here, we present the proof of principle
of a strategy for reprogramming to pluripotency
facilitated by small molecules that interfere with
the somatic transcriptional memory. We show that
mild chemical targeting of the acetyllysine-binding
pockets of the BET bromodomains, the transcrip-
tional bookmarking domains, robustly enhances
reprogramming. Furthermore, we show that chemi-
cal targeting of the transcriptional bookmarking
BET bromodomains downregulates or turns off the
expression of somatic genes in both naive and re-
programming fibroblasts. Chemical blocking of the
BET bromodomains also results in loss of fibroblast
morphology early in reprogramming. We there-
fore experimentally demonstrate that cell fate con-
version can be achieved by chemically targeting the
transcriptional bookmarking BET bromodomains
responsible for transcriptional memory.
INTRODUCTION
Conversion of somatic cells into the pluripotent state is in princi-
ple a process of epigenetic modulation. Specific and directed
modulation of epigenetic status on a genome-wide scale, as
for pluripotent reprogramming, is complicated and difficult (Hu,
2014a, 2014b). We hypothesized that targeted chemical inter-
vention of somatic epigenetic reading and/or decoding may be
easier to achieve and could facilitate induction of pluripotent
stem cells (iPSCs). Each cell type has its unique transcriptome.
This uniquely expressed gene set defines the cell identity. How-3138 Cell Reports 16, 3138–3145, September 20, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://ever, duringmitosis, general and gene-specific transcription fac-
tors largely come off chromatin, and global transcription stops
(Gottesfeld and Forbes, 1997; Martı´nez-Balba´s et al., 1995; Par-
sons and Spencer, 1997). Upon exit from mitosis, each cell type
remembers its unique transcriptional details and faithfully re-
sumes its defined transcription. The released transcriptional
machinery homes in to the defined places after mitosis. This
transcriptional memory during cell divisions is realized by a
process called transcriptional bookmarking onmitotic chromatin
(Sarge and Park-Sarge, 2009; Zaidi et al., 2010). Because re-
programming has to erase the somatic transcription, it is
tempting to facilitate pluripotent reprogramming by perturbing
somatic transcriptional memory, which is done by specifically
disrupting the somatic transcriptional bookmarking during
mitosis.
One family of mitotic proteins responsible for transcriptional
memory is the bromodomain and extra-terminal domain (BET)
proteins (Devaiah and Singer, 2013; Dey et al., 2009; Kanno
et al., 2004; Zhao et al., 2011). They are characterized by two tan-
dem bromodomains, which bind to the acetylated histones. BET
proteins are established epigenetic readers due to their ability to
bind to the active acetylated histones via their bromodomains
(Belkina and Denis, 2012), and they positively regulate the
actively expressed genes in general (LeRoy et al., 2008). Unlike
other transcriptional regulators, BET proteins remain on mitotic
chromatin during all stages of mitosis when the general tran-
scriptional machinery temporally disengages mitotic chromatin.
It is suggested that this continuous association of BET proteins
with mitotic chromatin contributes to the transcriptional memory
by bookmarking the formerly active genes (Devaiah and Singer,
2013; Dey et al., 2009; Kanno et al., 2004; Zhao et al., 2011).
Among these BET regulated genes are those defining cell iden-
tities. For example, BRD4 is critical in the control of transcrip-
tional elongation of pluripotent genes to maintain embryonic
stem cell identity (Di Micco et al., 2014; Wu et al., 2015). There-
fore, the transcriptional bookmarking or reading bromodomainsuthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
of BET proteins is an ideal target for chemical manipulation in cell
fate conversions.
Here, we report that mild inhibition of BET bromodomains with
small molecules significantly enhances iPSC reprogramming via
reduction or erasure of expressions for a large set of fibroblast
genes. Our findings also raise a concern about the highly antic-
ipated use of BET inhibitors in cancer patients.
RESULTS
Identification of a Set of Human Fibroblast-Specific
Genes and Insufficient Erasure of Fibroblast Program by
the Canonical Reprogramming Factors
We first examined the number of fibroblast-specific genes that
have to be downregulated during reprogramming. These fibro-
blast genes include not only those exclusively expressed in fi-
broblasts but also those with higher expression in fibroblasts
than in human pluripotent stem cells (hPSCs). We have
sequenced the RNA from two human embryonic stem cell
(hESC) lines (H1 and H9). To avoid mouse RNA contamination
from feeder cells, those hESC lines are cultured in a xeno-free
culture system (Chen et al., 2011). We have also sequenced the
RNA from three human BJ fibroblast samples (GSE66798),
the starting cells in our reprogramming experiments. We used
the DESeq algorithm for RNA sequencing (RNA-seq) differential
analyses because of its sensitivity (Dillies et al., 2013). Differen-
tial expression analysis showed that as many as 3,148 genes
have higher expression in fibroblasts than in hESCs (1.5 times
or more, p < 0.05; normalized averaged DESeq read counts
[ADRCs] for BJ are greater than 50) (Table S1). Of these
3,148 fibroblast-specific genes, 1,017 are considered not
expressed in hESCs (ADRC for hESCs < 50). These indicate
that we have to shut down the expression of these 1,017
genes, and downregulate the remaining 2,131 genes for suc-
cessful reprogramming. Downregulation of somatic genes is
generally an early event during reprogramming. Next, we
sequenced the RNA from the same human fibroblasts trans-
duced with reprogramming factors OCT4, SOX2, and KLF4
(OSK), and then we examined the degree of downregulation
of these fibroblast genes early in the reprogramming (48 hr after
transduction). As many as 1,940 genes were downregulated
by OSK overexpression, but only 510 of those genes have
fibroblast-specific transcription (Figure S3A; Table S1). These
results indicate insufficient erasure of fibroblast-specific tran-
scription and significant aberrant downregulation of transcrip-
tion by OSK early in reprogramming.
Mild Targeting of the Bookmarking Pockets of the BET
Bromodomains Enhances Human iPSC Reprogramming
Small molecules with specific binding to the acetyllysine-bind-
ing pockets of the BET bromodomains have been developed
(Dawson et al., 2011; Devaiah et al., 2012; Filippakopoulos
et al., 2010). Given the roles of BET proteins in transcriptional
bookmarking, we explored the possibility that these chemicals
may be used to promote iPSC reprogramming via de-book-
marking the somatic transcription. However, we and others
reported that chemical BET inhibition severely impaired reprog-
ramming (Liu et al., 2014; Shao et al., 2016). We observedextensive cell death during reprogramming when 500 nM
(+)-JQ1 (or JQ1), the prototype BET chemical inhibitor, was
included in the reprogramming media for 3 to 5 consecutive
days (data not shown). This concentration is widely used to
kill cancer cells (Delmore et al., 2011; Mertz et al., 2011).
Because this concentration impairs the basic BET functions
for cell survival, we examined the effect of transient BET inhibi-
tion on reprogramming. Increased reprogramming activities
were observed when the reprogramming cells were treated
with JQ1 intermittently on days 3 and 5 at 100, 250, 500, and
up to 1,000 nM (Figure 1A). A scrutiny of the reprogramming
data from M.A. Esteban’s group revealed a consistent increase
of reprogramming activity upon JQ1 treatment at early stages
of reprogramming, although the enhancement was low (Liu
et al., 2014). Encouraged by this finding, we conducted a
dosage study with reduced concentrations of JQ1. We
observed a dramatic increase in reprogramming activities for
all low doses of JQ1 from 10 to 100 nM, even when used for
an extended time (Figures 1B and S1A). The highest reprog-
ramming activity was displayed by 50 nM of JQ1 (Figures
1B–1D and S1A). Under the optimized condition (Figure 1H),
JQ1 enhanced reprogramming by 22-fold on average (Fig-
ure 1C). We then used 50 nM of JQ1 in our remaining studies.
A time course study showed that JQ1 had an early impact
on reprogramming (Figures 1E and S1B). Later treatments still
benefitted reprogramming, but the reprogramming activity
decreased over time (Figures 1E and S1B). Continuous BET
inhibition for 11 days from day 3 to 14 displayed the highest re-
programming activity (Figures 1E and S1B). However, further
treatment with JQ1 beyond day 14 impaired reprogramming
(data not shown). This is because human iPSCs have appeared
by then and this low concentration of JQ1 still impaired growth
of hPSCs (Figures S1E and S1F). This result is in agreement
with the report by M.A. Esteban’s group (Liu et al., 2014).
Their data showed that JQ1 treatment at a late stage of
reprogramming impairs reprogramming. Mouse reprogramming
is faster, and we suggest that their data reflect the negative
effect of JQ1 on iPSC growth rather than the reprogramming
process.
JQ1 is specific for BET bromodomains (Filippakopoulos et al.,
2010). The reprogramming activity of JQ1 was observed at low
concentrations, and reprogramming media were changed every
day. Therefore, it is unlikely that the observed reprogramming
activity is an off-target effect. To further rule out the possibility
of an off-target effect, we tested additional chemical inhibitors
specific for BET bromodomains. CPI203, a derivative of JQ1 (De-
vaiah et al., 2012), demonstrated robust reprogramming activity
at a lower concentration (Figures 1F and S1C). I-BET151 is a
structurally distinct BET-specific inhibitor (Dawson et al., 2011;
Smith et al., 2014). Our data showed that I-BET151 is also a
robust reprogramming promoter when used at a lower concen-
tration (Figures 1F and S1C). In addition, vehicle (DMSO) and
the inactive ()-JQ1, the enantiomer of (+)-JQ1, exhibited no re-
programming activity (Figures 1G and S1D). In agreement with
our observation that 50 nM is the optimal concentration for
reprogramming, we found that a combination of the three BET
inhibitors did not further improve reprogramming and even
slightly impaired reprogramming compared to 50 nM JQ1 aloneCell Reports 16, 3138–3145, September 20, 2016 3139
Figure 1. Mild Chemical Targeting of
Bromodomains with the BET Inhibitors
Enhances Reprogramming
(A) Transient BET inhibition promoted human iPSC
reprogramming. BJ cells transduced with OSK
were treated at days 3 and 5 for 24 hr each day at
the concentrations indicated. n = 3.
(B) Effect of JQ1 dosage on reprogramming. JQ1
treatments were performed from day 3 to 14 at the
concentrations indicated. n = 3.
(C) JQ1 reprogramming efficiency as calculated by
the percentage of TRA-1-60+ colonies based on
the number of starting cells, at the optimized
conditions (50 nM, from day 3 to 14). n = 12.
(D) Representative images of reprogramming
dishes stained for TRA-1-60, showing high re-
programming activity of JQ1.
(E) Time course of JQ1 reprogramming activity
(50 nM). n = 3.
(F) Other BET inhibitors demonstrated re-
programming activity when used at low concen-
trations from day 3 to 14. n = 3.
(G) Inactive ()-JQ1 and DMSO do not exhibit re-
programming activity. Reprogramming cells were
treated with chemicals as indicated from day 3 to
14. n = 3.
(H) Schematic for the optimized JQ1 reprogram-
ming protocol in a chemically defined medium.
D, day. **p < 0.01; ***p < 0.001. Data are presented
as mean ± SD in (A)–(C) and (E)–(G). See also
Figures S1 and S2.(Figure S1G). This also suggests that these three distinct inhibi-
tors hit the same target, because a higher concentration of JQ1
alone also demonstrated decreased reprogramming activity
(Figures 1B and S1A). Collectively, these data indicate that the
enhancement of reprogramming is specific for BET bromodo-
main targeting.
Vitamin C (Vc) has been reported to promote reprogramming
(Esteban et al., 2010). Because the xeno-free reprogramming
media we used contains Vc (Chen et al., 2011), we conducted
Vc dropout experiments to compare the reprogramming activ-
ities of JQ1 with those of Vc. We used the optimized concentra-
tion of Vc (64 mg/ml) based on previous reports (Chen et al., 2011,
2013; Esteban et al., 2010; Wang et al., 2011). Vc displayed little
reprogramming activity in our system (Figures 1G and S1D). This
discrepancy might be a result of different media and the reprog-
ramming system used in the current study. Our results are in
agreement with another report that used the same reprogram-
ming system as we did (Chen et al., 2011).3140 Cell Reports 16, 3138–3145, September 20, 2016We conducted our reprogramming
in three-factor reprogramming, consid-
ering that c-MYC is slightly detrimental
to reprogramming in defined media
(Shao et al., 2016; Xu et al., 2013).
Nevertheless, we found that JQ1 also
enhanced reprogramming in the pres-
ence of c-MYC (Figure S2). The
observed enhanced reprogramming ac-
tivity for BET inhibitors was not due toshortened kinetics of reprogramming by JQ1, because
enumeration of the TRA-1-60+ colonies on day 30 had similar
results (Figure S2).
BET iPSCs Are Pluripotent
Using various criteria, we next tested the pluripotency of the
iPSCs generated using BET inhibitors (BETiPSCs). Transgene
silencing is a hallmark of advanced reprogramming. All three
canonical reprogramming factors are co-expressed with GFP
via 2A peptide in our reprogramming constructs (Shao et al.,
2016); therefore, GFP expression provides a sensitive mea-
surement of transgene silencing. BETiPSCs did not express
GFP (Figure 2B), indicating silencing of the transgenes.
BETiPSCs activated the pluripotent transcription factors
OCT4, NANOG, and SOX2 and expressed the pluripotent
surface markers TRA-1-60 and TRA-1-81 (Figure 2A) (Kang
et al., 2016). The expression of OCT4 was not from the trans-
genic OCT4, because the multiple GFPs co-expressed with
Figure 2. BETiPSCs Are Pluripotent
(A) Immunocytochemistry of BETiPSCs showing expression of pluripotent master transcription factors and pluripotent surface markers as indicated.
(B) BETiPSCs silenced transgenes as indicated by the absence of GFP co-expressed with reprogramming factors as mediated by 2A peptide.
(C) PCAs of BETiPSCs and selected cell types based on RNA-seq data (GSE75364 and GSE66798).
(D) Euclidean distance of BETiPSCs from somatic cells, hESCs, and previously established iPSC lines based on RNA-seq data.
(E) H&E staining of BETiPSC-derived teratoma, showing the ability to generate tissues of all three embryonic germ layers.
(F) Normal karyotypes of BETiPSCs.
Scale bars in (B), 100 mm; bars in (A) and (E), 50 mm. K, human keratinocytes.OSK were efficiently silenced (Figure 2B). BETiPSCs had a
transcriptome similar to those of hESCs and the established
human iPSCs (Figures 2C and 2D). BETiPSCs had the ability
to generate teratomas containing cells that represent all three
embryonic germ layers (Figure 2E). BETiPSCs had normal kar-
yotypes (Figure 2F).
Mild Chemical Targeting of BET Bromodomains Erases
Fibroblast Transcription
Next, we test whether chemical targeting of the BET bromodo-
mains erases somatic transcription. We first conducted deep
sequencing of RNA of the starting human fibroblasts. Exposure
of fibroblasts to 50 nM JQ1 for 48 hr downregulated 551 genes(Figure 3A2; Table S2). Of these 551 downregulated genes, 390
(70.8%) demonstrated higher expression in fibroblasts than in
hPSCs (Figures 3A3 and 3A4; Table S2). Furthermore, of these
390 JQ1-downregulated fibroblast genes, 162 (41.5%) are
deemed no expression in hPSCs (Figures 3A3 and 3A4; Table
S2). In contrast, only 95 genes were upregulated by JQ1 (Fig-
ure 3A2). BET proteins are widely regarded as positive regula-
tors of gene expression. This 5.83 bias in numbers toward
downregulated genes upon BET inhibition indicates a predom-
inant loss of transcriptional memory. These results indicate that
as expected, mild BET bromodomain perturbation has damp-
ened the transcriptional memory of the fibroblast gene
expression.Cell Reports 16, 3138–3145, September 20, 2016 3141
Chemical Targeting of the BET Bromodomains Erases
Fibroblast Transcription during Reprogramming
We further sequenced the RNA from reprogramming cells
treated with JQ1 after transduction of reprogramming factors
OSK. We found that twice as many genes (1,182 versus 551
genes) were downregulated by JQ1 in reprogramming cells
compared to naive fibroblasts (Figure 3B2; Table S3). This indi-
cates a synergistic effect between JQ1 and the reprogramming
factors. As in non-transduced fibroblasts, a large portion of the
JQ1-downregulated genes in the OSK-overexpressing reprog-
ramming cells had higher expression in fibroblasts than in
hPSCs (651 of 1,182) (Figures 3B1, 3B3, and 3B4; Table S4).
Furthermore, 270 of the 651 fibroblast-enriched genes
(41.5%) were deemed no expression in hPSCs (Figures 3B3
and 3B4; Table S4). Therefore, as seen in the non-transduced
fibroblasts, JQ1 targeting of the BET bromodomains has
reduced and/or erased the fibroblast-specific transcription in
reprogramming cells.
As described earlier, the OSK factors downregulate 510 fibro-
blast-specific genes. It appears that OSK and JQ1 treatment
largely targeted different sets of fibroblast-specific genes under
our conditions, and there were only 104 genes targeted by both
OSK and JQ1 (Figures S3A and S3B). For these 104 fibroblast
genes, addition of JQ1 showed a synergistic effect (Figures
S3C and S3D). However, there appears to be some interplay be-
tween BET inhibition and OSK, because we observed that more
genes were downregulated by JQ1 in reprogramming cells, and
some genes downregulated by JQ1 in naive cells were not on the
list of genes downregulated by JQ1 in reprogramming cells (Fig-
ures S3E and S3F). In our current data, BET inhibition did not
downregulate all fibroblast-specific genes. There may be three
reasons. First, BET proteins may not regulate all fibroblast-spe-
cific genes. Second, our RNA-seqwas performed at early stages
of reprogramming. Our RNA-seq may not reveal all changes
caused by BET inhibition. Unfortunately, analyses at later stages
become more complicated because the cell population be-
comes more heterogeneous. Third, disruption of other fibroblast
transcription upon short treatment may require a more severe
BET inhibition, but those conditions are not relevant to the re-
programming mechanistic study.
In agreement with the erasure of fibroblast transcription by
BET inhibition, we observed a loss of fibroblast morphology
upon JQ1 treatment early in reprogramming (Figures 3D and
S4). The same reprogramming BJ cells treated with the inactive
enantiomer ()-JQ1 mostly retained the spindle shape charac-
teristic of fibroblasts, while most cells treated with JQ1 became
polygonal or even round, similar to those of hPSCs (compare
Figures 3C and 3D with S4). Other BET inhibitors caused similar
changes in cell morphology early in reprogramming (Figures 3E
and S4).
Compared to the non-transduced fibroblasts, 9.2 times more
genes (878 versus 95) were upregulated by JQ1 in the reprog-
ramming cells overexpressing OSK (Figures 3A2 and 3B2), again
indicating a synergistic effect between JQ1 and OSK. Among
these JQ1-upregulated genes, 33.6% had higher expression in
hPSCs, 22% had lower expression in hPSCs, and the remaining
44.4% did not have significant changes in expression levels
between fibroblasts and hPSCs (Figure 3B3). Based on these3142 Cell Reports 16, 3138–3145, September 20, 2016results, the JQ1 impact on the upregulated genes is more pro-
miscuous in terms of reprogramming, but a pro-reprogramming
upregulation prevails when the reprogramming factors are
present (Figure 3).
DISCUSSION
We have demonstrated that mild chemical targeting of the BET
bookmarking bromodomains significantly enhanced human
iPSC reprogramming. In fibroblasts, this targeted blockage of
the acetyllysine-binding pockets in the BET bromodomains
also resulted in reduction and/or loss of expression of a large
set of fibroblast genes. In addition, we showed that mild chemi-
cal blocking of this acetyllysine-binding activity acted in concert
with the reprogramming factors OSK to further downregulate the
somatic transcription. Figure 4 is a schematic model for facili-
tating pluripotent reprogramming by de-bookmarking somatic
transcription via targeting the BET bromodomains. In brief,
BET proteins bookmark the active fibroblast genes during
mitosis. This bookmarking ensures the resumption of the cell-
type-specific transcription upon exit from mitosis. When BET in-
hibitors are included in the growth media, BET proteins fail to
bookmark the fibroblast transcription due to their displacement
by BET chemical inhibitors. This de-bookmarking results in
reduction and/or loss of the fibroblast transcription and eventu-
ally enhances reprogramming. In nature, bookmarking is a
concept for mitosis. In an experimental setting, this bookmarking
may be required in interphase as well for the maintenance of so-
matic transcription. Therefore, the concept of de-bookmarking
should not be restricted to mitosis. A lack of bookmarking via
experimental interference in interphase also results in a loss of
somatic transcription.
In the future, it will beworth further testing the de-bookmarking
theory in other cell fate conversions, for example, direct reprog-
ramming from fibroblasts to myocardiocytes or other functional
somatic cells. BET perturbation of transcriptional memory may
be a general mechanism in cell fate conversions. One publication
indicated this possibility already. BET inhibitors promoted direct
conversion of murine fibroblasts to neural cells and disrupted
the fibroblast expression programs (Li et al., 2015). It is possible
that fibroblast-specific transcriptional programs are regulated by
multiple members of BET proteins, considering that current BET
chemical inhibitors target all three ubiquitous BET proteins:
BRD2, BRD3, and BRD4. Further elegant research is required
to understand the exact molecular mechanisms underlying the
reprogramming activity of chemical BET inhibition.
BET inhibitors are highly anticipated as a pharmacological
intervention of tumor development. Our data and a previous
report that BET perturbation can shift cell fates is a cautionary
sign for their use in patients (Li et al., 2015). S.W. Lowe’s group
demonstrated that Brd4 knockdown in a mouse model resulted
in a loss of tissue homeostasis, including skin hyperplasia and
depletion of intestinal stem cells (Bolden et al., 2014). Further
research on possible induction of tumorigenesis and disruptions
of tissue homeostasis by BET inhibition is warranted, because
iPSCs are by nature tumorigenic and many cell types express
SOX2 and/or KLF4, the two canonical reprogramming factors
used with BET inhibitors in the current study.
Figure 3. Chemical Targeting of the BET
Bromodomains Results in Reduction and
Loss of Fibroblast Transcription both in
Early Reprogramming Fibroblasts and in
Naive Fibroblasts
(A and B) Heatmap comparisons showing re-
duction and/or loss of expression of the fibro-
blast genes by JQ1 treatment at 50 nM for 48 hr
of the non-transduced naive BJ fibroblasts (A1,
the same 390 genes as in A4) and of the re-
programming fibroblasts (B1, the same 651
genes as in B4). Summary for the impact of mild
BET inhibition on transcription in naive BJ
fibroblasts (A2) and in reprogramming BJ cells
(B2). Summary for the impact of the JQ1-
affected genes on reprogramming based on their
expression status in hPSCs relative to that in
fibroblasts. A3 is for those in non-transduced
BJ cells, while B3 is for the affected genes in
reprogramming cells. Heatmap presentation for
the expression levels in hPSCs and BJ, of the
fibroblast genes, that are large subsets of the
JQ1-downregulated genes in the non-transduced
fibroblasts (A4, the same 390 genes as in A1)
and in the reprogramming BJ cells (B4, the same
651 genes as in B1). Heatmap expression
levels in (A1), (B1), (A4), and (B4) are log2 (DESeq
read counts of RNA-seq). Key in (A2), (A3),
(B2), and (B3): upward arrows, upregulation;
downward arrows, downregulation; red arrows,
elevated or decreased expression in hPSCs
compared to expression in fibroblasts; forward
arrows, positive changes for pluripotency;
hammer signs, negative changes for pluripo-
tency. Thickness indicates the approximate
impact on reprogramming based on the number
of genes affected. Counts of genes affected or
compared are listed, with the corresponding
percentages included in parentheses. The cor-
responding denominators for percentage calculations are indicated with the same highlights for the percentages (blue or underline). See also Tables S2,
S3, and S4.
(C–E) Cell morphologies of BJ cells on day 5 after treatment with ()-JQ1 (50 nM), (+)-JQ1 (50 nM), and I-BET151 (100 nM). Bars, 50 mM. See also Figures S3
and S4 and Tables S1, S2, S3, and S4.EXPERIMENTAL PROCEDURES
Reprogramming
UAB Institutional Animal Care and Use Committee approved the use of mice,
and the animal protocols comply with ethical regulations. BJ fibroblasts were
seeded into 6-well plates at 13 105 cells/well. Twenty-four hours after plating,
premixed OSK viruses (OCT4, 10 MOI; SOX2, 5 MOI; and KLF4, 5 MOI)
were added in the presence of polybrene at 4 mg/ml. The next morning, viruses
were removed by replacing the spent media with fresh fibroblast media.
Then, 24 hr after transduction, the transduced cells were reseeded at 3 3
104 to 43 104 cells/well into matrigel-coated 6-well plates. The next day, fibro-
blast medium was replaced with reprogramming media (E6 medium: DMEM/
F12, 13.6 mg/l sodium selenium, 1.7 g/l NaHCO3, 1 g/l sodium chloride,
10 mg/l FGF2, 20 mg/l insulin, and 10.7 mg/l transferrin; or E7 medium: E6
medium + 64 mg/l L-ascorbic acid 2-phosphate sesquimagnesium) with or
without small molecules JQ1 (Catalog No. 4499, Tocris Bioscience),
iBET-151(Catalog No. 4650, Tocris), or CPI203 (C6132, LKT Laboratories).
Starting from day 12 to 14, E8 media were used. On day 21 of reprogramming,
reprogramming cells were stained for TRA-1-60.
RNA-Seq
RNA-seq used 500 ng of total RNA. Polyadenylated RNAs were isolated using
NEBNext Magnetic Oligo d(T)25 Beads. Next, first-strand synthesis wasperformed using the NEBNext RNA first-strand synthesis module (NE Biolabs).
Immediately, directional second-strand synthesis was performed using the
NEBNext Ultra Directional Second-Strand Synthesis kit. The NEBNext DNA
Library Prep Master Mix Set for Illumina was then used to prepare individually
bar-coded next-generation sequencing expression libraries per the manufac-
turer’s recommended protocol. Library quality was assessed using the Qubit
2.0 Fluorometer, and library concentration was estimated by using a DNA
1000 Chip on an Agilent 2100 Bioanalyzer. Accurate quantification for
sequencing applications was determined using the qPCR-based Kapa
Biosystems Library Quantification Kit. Each library was diluted to a final
concentration of 12.5 nM and pooled in an equimolar ratio before clustering.
Paired-end sequencing was performed on an Illumina HiSeq2500 sequencer
with a high-output mode. Image analysis and base calling were performed
using the standard Illumina pipeline implemented in real-time analysis (RTA).
Raw reads were de-multiplexed using bcl2fastq Conversion Software
(Illumina) with default settings.
Bioinformatics
We obtained around 25 million paired 50 bp reads for each sample. RNA-seq
reads weremapped to the human reference genome (GRCh37/hg19) using the
STAR aligner (v.2.3.0e r291) (Dobin et al., 2013). The alignment was guided by
a Gene Transfer File (GTF version GRCh37.70). The read per million (RPM)
normalized BigWig files were generated using Bedtools (v.2.17.0) (QuinlanCell Reports 16, 3138–3145, September 20, 2016 3143
Figure 4. A Model for Reprogramming by Transcriptional De-bookmarking via Chemical Targeting of the BET Bromodomains
(A) In the absence of BET inhibitors, somatic genes continue to express and reprogramming is compromised.
(B) JQ1 displaces BET proteins and de-bookmarks somatic fibroblast genes in mitosis and in interphase to promote loss or reduction of expression for a large set
of fibroblast genes during reprogramming.and Hall, 2010) and the bedGraphToBigWig tool (v.4). Read count tables
were generated using HTSeq (v.0.6.0) based on the Ensembl gene annotation
file (Ensembl GTF version GRCh37.70) (Anders et al., 2015). All read
count tables were then corrected for their library size differences based on
their geometric library size factors calculated using the DESeq R package
(v.3.0) (Anders and Huber, 2010), and differential expression (DE) analysis
was performed. To compare the level of similarity among the samples in
our dataset based on their normalized gene expression, we used two
methods: classical multidimensional scaling or principal-component analysis
(PCA) and Euclidean distance-based sample clustering. All downstream
statistical analyses and data visualizations were performed in R (v.3.1.1)
(http://www.r-project.org/).
Statistics
For reprogramming analyses, we conducted each experiment at least in
triplicate and counted the TRA-1-60+ colonies. The data are shown as
mean ± SD. Statistics was conducted using a two-tailed, unpaired t test for
statistical analysis. Significance designations are as follows: significance,
*p < 0.05; very significant, **p < 0.01; extremely significant, ***p < 0.001.
For deferential expression analyses, we used the nbinomTest function in the
DESeq package after correcting for library sizes. For PCA and Euclidean
distance analyses, we performed dispersion estimates of the count data
using the estimateDispersions function in blind mode, and we used the
varianceStabilizingTransformation function to transform the count data for
fixing for large or infinite log2 (expression values) in genes with low or zero
expression. We employed DESeq’s plotPCA function to calculate the first
two principle components, and we created the two-dimensional plot using
the ggplot2 package. For distance analysis, we used the R dist function to
calculate the sample distances in the transformed count data (as explained
earlier) by setting the method as Euclidean (default).3144 Cell Reports 16, 3138–3145, September 20, 2016ACCESSION NUMBERS
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